# US 2003/0224349 A1 · Rapid assay to assess the potential for glucocorticoid analogs to promote the differentiation of human osteoblasts and predict bone safety

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0224349 A1
- Document ID: US20030224349A1
- Status: Published application
- Kind: A1
- Application number: 10/452,853
- Filed: 2003-06-02
- Published: 2003-12-04
- Earliest claimed: 2002-05-31
- Assignees: Pfizer Inc.
- Inventors: Leonard Buckbinder
- Web page: https://patentgrep.com/patent/US20030224349A1

## CPC

- G01N 33/743: {Steroid hormones}
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

This invention relates to in vitro screening and assay methods for the selection of anti-inflammatory compounds that exhibit minimized effects on the differentiation of human osteoblasts.

## Claims

### Claim 1

A method of selecting anti-inflammatory compounds that minimize osteoblast differentiation from those which cause higher levels of osteoblast differentiation, comprising:
a) identifying a compound which binds the glucocorticoid receptor;
b) demonstrating anti-inflammatory activity of the compound; and
c) determining the capacity of the compound to stimulate the differentiation of osteoblasts.

### Claim 2

A method to identify agonists of the glucocorticoid receptor that dissociate anti-inflammatory efficacy from bone side effects, comprising:
a) identifying a compound which binds the glucocorticoid receptor (Kd<10 uM) as determined by competition binding using a known reference compound tracer;
b) demonstrating anti-inflammatory activity of the compound utilizing one or more cell-based assays and/or animal models; and
c) determining the capacity of the compound to stimulate the differentiation of osteoblasts.

### Claim 3 (depends on 2)

The method of claim 2 where the differentiation of osteoblasts is determined by the alkaline phosphatase method.

### Claim 4 (depends on 2)

The method of claim 2 where the differentiation of osteoblasts is determined by Von Kossa staining.

### Claim 5 (depends on 3)

The assay of claim 3 where alkaline phosphatase activity is determined by colorimetric methods.

### Claim 6 (depends on 2)

The method of claim 2 where the anti-inflammatory activity is demonstrated in a cell-based assay.

### Claim 7 (depends on 6)

The method of claim 6 where the cell-based assay utilizes SW1353 cells.

### Claim 8

An assay to determine the effect on osteoblast differentiation of an anti-inflammatory compound comprising cultivating primary human osteoblasts in the presence of the compound and determining the amount of osteoblast differentiation of the cells after a period of from about 7 to about 13 days.

### Claim 9 (depends on 8)

The method of claim 8 where the detection of differentiation is determined by alkaline phosphatase activity.

### Claim 10

An assay to determine the dose dependent effect on osteoblast differentiation of an anti-inflammatory compound comprising
a] cultivating primary human osteoblasts in the presence of a first amount of the compound;
b] cultivating primary human osteoblasts in the presence of a different amount the compound;
c] repeating step b with as many different amounts of the test compound as desired; and
d] determining the amount of osteoblast differentiation at each concentration of added component after a period of from about 7 to about 13 days.
